Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study

Sourrouille, Isabelle; Macovei, R.; Faron, Matthieu; Péchoux, C. Le; Mir, Olivier; Adam, Julien; Dumont, Sarah; Terrier, Philippe; Cesne, Axel Le; Honoré, Charles

doi:10.1245/s10434-018-6529-z

Cited by 7 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sourrouille et al also noted that individuals over 70 years of age undergoing RPS had a mortality rate of 8% and a serious postoperative complication rate of 32%. However, it is noteworthy that the 5-year recurrence-free survival rate of elderly patients can also reach 52% [ 17 ]. Therefore, age is not a contraindication to RPS surgery.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma

Zhuang

Chen

et al. 2023

BMC Surg

View full text Add to dashboard Cite

Background Surgery is the cornerstone of the treatment for primary retroperitoneal sarcoma (RPS). The purpose of this study was to establish a nomogram predictive model for predicting postoperative morbidity in primary RPS. Methods Clinicopathological data of patients who underwent radical resection from 2009 to 2021 were retrospectively analyzed. Risk factor analysis was performed using a logistic regression model, and modeling variables were selected based on Akaike Information Criterion. The nomogram prediction model was built on the basis of a binary logistic regression model and internally validated by calibration curves and concordance index. Results A total of 319 patients were enrolled, including 162 males (50.8%). 22.9% (n = 73) were over 65 years of age, and 70.2% (n = 224) had tumors larger than 10 cm. The most common histologic subtypes were well-differentiated liposarcoma (38.2%), dedifferentiated liposarcoma (25.1%) and leiomyosarcoma (7.8%). According to the Clavien–Dindo Classification, 96 (31.1%) and 31 (11.6%) patients had grade I–II complications and grade III–V complications, respectively. Age, tumor burden, location, operative time, number of combined organ resections, weighted resected organ score, estimated blood loss and packed RBC transfusion was used to construct the nomogram, and the concordance index of which was 0.795 (95% CI 0.746–0.844). and the calibration curve indicated a high agreement between predicted and actual rates. Conclusions Nomogram, a visual predictive tool that integrates multiple clinicopathological factors, can help physicians screen RPS patients at high risk for postoperative complications and provide a basis for early intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma

Zhuang

Chen

et al. 2023

BMC Surg

View full text Add to dashboard Cite

show abstract

“…The current treatment regimen improved survival rate up to 60% but many patients show mild to low response to chemotherapeutics, requiring higher doses and longer treatment periods [6,7]. In addition, sarcoma recurrence is extremely high, with high incidence of distant metastases, particularly to lungs [8]. Molecular breakthroughs in genomic sequencing techniques coupled with advances in experimental models have improved the deciphering of biological mechanisms underlying onset and progression of different types of sarcomas, resulting in the identification of reliable markers of diagnosis and prognosis [9].…”

Section: Introductionmentioning

confidence: 99%

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas

Mancarella,

Morrione,

Scotlandi

2023

IJMS

View full text Add to dashboard Cite

Sarcomas are heterogeneous bone and soft tissue cancers representing the second most common tumor type in children and adolescents. Histology and genetic profiling discovered more than 100 subtypes, which are characterized by peculiar molecular vulnerabilities. However, limited therapeutic options exist beyond standard therapy and clinical benefits from targeted therapies were observed only in a minority of patients with sarcomas. The rarity of these tumors, paucity of actionable mutations, and limitations in the chemical composition of current targeted therapies hindered the use of these approaches in sarcomas. Targeted protein degradation (TPD) is an innovative pharmacological modality to directly alter protein abundance with promising clinical potential in cancer, even for undruggable proteins. TPD is based on the use of small molecules called degraders or proteolysis-targeting chimeras (PROTACs), which trigger ubiquitin-dependent degradation of protein of interest. In this review, we will discuss major features of PROTAC and PROTAC-derived genetic systems for target validation and cancer treatment and focus on the potential of these approaches to overcome major issues connected to targeted therapies in sarcomas, including drug resistance, target specificity, and undruggable targets. A deeper understanding of these strategies might provide new fuel to drive molecular and personalized medicine to sarcomas.

show abstract

Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials

Tang

Tie

Wei

et al. 2021

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Long-Term Outcome After Surgery for a Localized Retroperitoneal Soft Tissue Sarcoma in Elderly Patients: Results from a Retrospective, Single-Center Study

Abstract: Curative surgery is feasible in selected elderly patients but with higher mortality and morbidity rates than in younger patients. It enables a prolonged survival. Future studies should focus on selection process to minimize postoperative mortality and morbidity.

Cited by 7 publications

References 29 publications

Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma

Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas

Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials

Contact Info

Product

Resources

About